TSHA Taysha Gene Therapies

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2025, and host a corporate update conference call and webcast on Tuesday, November 4, 2025, at 8:30 AM Eastern Time.

Conference Call Details

Tuesday, November 4, at 8:30 AM Eastern Time / 7:30 AM Central Time

Toll Free: 800-245-3047

International: 203-518-9765

Conference ID: TAYSHA

Webcast:

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit .

Company Contact:

Hayleigh Collins

Senior Director, Corporate Communications and Investor Relations

Taysha Gene Therapies, Inc.

Media Contact:

Carolyn Hawley

Inizio Evoke



EN
28/10/2025

Underlying

TSHATaysha Gene Therapies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Taysha Gene Therapies

 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and...

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials showing an unprecedented response rate Dosing of first patient in REVEAL pivotal trial scheduled for Q4 2025, with enrollment of additional patients expected to continue at multiple sites this quarte...

November 4, 2025 1 EN
 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results ...

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2025, and host a corporate update conference call and webcast on Tuesday, November 4, 2...

October 28, 2025 1 EN
 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in ...

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has demonstrated compelling Part A REVEAL Phase 1/2 safety and efficacy data, received FDA Breakthrough Therapy designation and is advancing with a clear path to potential registration Dosing of the first patient in the REVEAL pivotal ...

October 16, 2025 1 EN
 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies Presents New Supplemental Data Analysis from Par...

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced review by independent central raters New supplemental analysis of validated, structured efficacy scales provides supportive evidence of additional functional gains, with 100% of patients demonstrating multiple skill gai...

October 9, 2025 1 EN
 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2025, the Compensation Committee of Taysha's Board of Directors granted seven new employees, in the aggregate, options to purchase 1,289,600 shares of the Company's common stock in conne...

October 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch